Review Article

Nitrofurantoin-Induced Hepatotoxicity: A Rare Yet Serious Complication

Authors: Sami A. Sakaan, PharmD, BCPS, Jennifer D. Twilla, PharmD, BCPS, Justin B. Usery, PharmD, BCPS, John C. Winton, MD, Timothy H. Self, PharmD

Abstract

Nitrofurantoin is a commonly prescribed antibiotic for thetreatment of recurrent uncomplicated urinary tract infections. Its importance has been emphasized by the current international clinical practice guidelines for the management of uncomplicated cystitis. Since its introduction into clinical practice, nitrofurantoin has been
associated with various adverse effects, including hepatotoxicity.

We searched the English-language literature using PubMed and SCOPUS for the period 1961 through the end of February 2013. Key search terms included ‘‘nitrofurantoin AND hepatotoxicity’’ as well as ‘‘nitrofurantoin AND hepatitis.’’ When studies or case reports were found, we assessed articles cited in those publications.

A broad spectrum of liver toxicity associated with nitrofurantoin use has been reported, ranging from acute hepatitis, granulomatous reaction, cholestasis, or autoimmune-mediated hepatitis to chronic active hepatitis that could lead to cirrhosis or death. The mechanism of hepatotoxicity is poorly understood, but it is believed to be the result of an immunologic process or a direct cytotoxic reaction. It has been postulated that prolonged exposure to nitrofurantoin, female sex, advanced age, and reduced renal function increase the risk of developing hepatotoxicity. For the management of severe cases, corticosteroids have been used along with nitrofurantoin discontinuation. Because of
mixed results, the utility of corticosteroids has not been proven and should be used judiciously.

Given the severity and seriousness of the adverse effect of hepatotoxicity, clinicians should weigh the risks and benefits of nitrofurantoin before initiating therapy, especially in long-term prophylaxis in high-risk patients. Clinicians also should be well versed in recognizing and managing liver injury associated with nitrofurantoin.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society of Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-e120.
 
2. Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol 2004;172:448-453.
 
3. Ernaelsteen D, Williams R. Jaundice due to nitrofurantoin. Gastroenterology 1961;41:590-593.
 
4. Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988;8:599-606.
 
5. Holmberg L, Boman G, Bo¨ttiger LE, et al. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980;69:733-738.
 
6. Penn RG, Griffin JP. Adverse reactions to nitrofurantoin in the United Kingdom, Sweden, and Holland. Br Med J (Clin Res Ed) 1982;284:1440-1442.
 
7. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040-2048.
 
8. Iwarson S, Lindberg J, Lundin P. Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases. Scand J Gastroenterol 1979;14:497-502.
 
9. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980;92:14-19.
 
10. Klemola H, Penttila O, Runeberg L, et al. Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol 1975;10:501-505.
 
11. Stromberg A, Wengle B. Chronic active hepatitis induced by nitrofurantoin. Br Med J 1976;2:174-175.
 
12. Mollison LC, Angus P, Richards M, et al. Hepatitis due to nitrofurantoin. Med J Aust 1992;156:347-349.
 
13. Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002;4:184-186.
 
14. Galan MV, Potts JA, Silverman AL, et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005;39:64-67.
 
15. Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Reports 2010;4:311.
 
16. Coraggio MJ, Gross TP, Roscelli JD. Nitrofurantoin toxicity in children. Pediatr Infect Dis J 1989;8:163-166.
 
17. Cook GC, Sherlock S. Jaundice and its relation to therapeutic agents. Lancet 1965;1:175-179.
 
18. Jokela S. Liver disease due to nitrofurantoin. Gastroenterology 1967;53:306-311.
 
19. Lindberg J, Lindholm A, Lundin P, et al. Trigger factors and HL-A antigens in chronic active hepatitis. Br Med J 1975;4:77-79.
 
20. Fagrell B, Strandberg I, Wengle B. A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report. Acta Med Scand 1976;199:237-239.
 
21. Black M, Rabin L, Schatz N. Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med 1980;92:62-64.
 
22. Engel JJ, Vogt TR, Wilson DE. Cholestatic hepatitis after administration of furan derivatives. Arch Intern Med 1975;135:733-735.
 
23. Hatoff DE, Cohen M, Schweigert BF, et al. Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen. Am J Med 1979;67:117-121.
 
24. Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous hepatitis. Urology 1981;18:177-178.
 
25. Miller AR, Addis BJ, Clarke PD. Nitrofurantoin and chronic active hepatitis. Ann Intern Med 1982;97:452.
 
26. Berry WR, Warren GH, Reichen J. Nitrofurantoin-induced cholestatic hepatitis from cow’s milk in a teenaged boy. West J Med 1984;140:278-280.
 
27. Young TL, Achkar E, Tuthill R, et al. Chronic active hepatitis induced by nitrofurantoin. Cleve Clin Q 1985;52:253-256.
 
28. Burger HC, Meiring JL, Nel PJ. Chronic active hepatitis caused by nitrofurantoin: a case report. S Afr Med J 1985;67:125-126.
 
29. Thomson RG, James OF. Seventh-nerve palsy and hepatitis associated with nitrofurantoin. Hum Toxicol 1986;5:387-388.
 
30. Reinhart HH, Reinhart E, Korlipara P, et al. Combined nitrofurantoin toxicity to liver and lung. Gastroenterology 1992;102:1396-1399.
 
31. Hebert MF, Roberts JP. Endstage liver disease associated with nitrofurntoin requiring liver transplantation. Ann Pharmacother 1993;27:1193-1194.
 
32. Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol 1992;87:891-893.
 
33. Mulberg AE, Bell LM. Fatal cholestatic hepatitis and multisystem failure associated with nitrofurantoin. J Pediatr Gastroenterol Nutr 1993;17:307-309.
 
34. Burgert SJ, Burke JP, Box TD. Reversible nitrofurantoin-induced chronic active hepatitis and hepatic cirrhosis in a patient awaiting liver transplantation. Transplantation 1995;59:448-449.
 
35. Schattner A, Von der Walde J, Kozak N, et al. Nitrofurantoin-induced immune-mediated lung and liver disease.Am J Med Sci 1999;317:336-340.
 
36. Edoute Y, Karmon Y, Roguin A, et al. Fatal liver necrosis associated with the use of nitrofurantoin. Isr Med Assoc J 2001;3:382-383.
 
37. Mackenzie FD, Storie WJ. Pulmonary and hepatic toxicity due to nitrofurantoin. J Pharm Pract Res 2004;34:134-135.
 
38. Peedikayil MC, Dahhan TI, Al Ashgar Hi. Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis. Ann Pharmacother 2006;40:1888-1889.
 
39. Kiang TK, Ford JA, Yoshida EM, et al. Nitrofurantoin-associated lung and liver toxicity leading to liver transplantation in a middle-aged patient. Can J Hosp Pharm 2011;64:262-270.
 
40. Koulaouzidis A, Bhat S, Moschos J, et al. Nitrofurantoin-induced lung-and hepatotoxicity. Ann Hepatol 2007;6:119-121.
 
41. Sargin G, Elbek O, Balantekin C, et al. Acute respiratory distress syndrome and hepatotoxicity associated with single dose nitrofurantoin use. Case Rep Pulmonol 2012;2012:465389.
 
42. Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419-1425.
 
43. Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals.Clin Liver Dis 2003;7:381-399.
 
44. Tolman KG. Nitrofurantoin and chronic active hepatitis. Ann Intern Med 1980;92:119-120.
 
45. Kelly BD, Heneghan MA, Bennani F, et al. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells.Am J Gastroenterol1998;93:819-821.
 
46. Boelsterli UA, Ho HK, Zhou S, et al. Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 2006;7:715-727.
 
47. Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 2013;47:106-111.
 
48. Drug record. Nitrofurantoin. http://livertox.nih.gov/Nitrofurantoin.htm. Accessed January 23, 2013.